Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01021865 · ClinicalTrials.gov registry record
Effects of Hyperglycemia on Myocardial Perfusion in Humans With and Without Type 2 Diabetes
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 33
- Enrollment target
NCT01021865: Completed study, sponsored by Mayo Clinic.
NCT01021865 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01021865 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 33 participants
- Enrollment target
Study Summary
The overall goal of this proposal is to determine the effects of acute hyperglycemia and its modulation by Glucagon-like Peptide-1 (GLP-1) on myocardial perfusion in type 2 diabetes (DM). This study plan utilizes myocardial contrast echocardiography (MCE) to explore a) the effects of acute hyperglycemia on myocardial perfusion and coronary flow reserve in individuals with and without DM; and b) the effects of GLP-1 on myocardial perfusion and coronary flow reserve during euglycemia and hyperglycemia in DM. The investigators will recruit individuals with and without DM matched for age, gender and degree of obesity. The investigators will measure myocardial perfusion at rest and during vasodilator stress (to ascertain coronary flow reserve) while subjects are under controlled pancreatic clamp conditions during euglycemia (glucose \~100 mg/dl) and hyperglycemia (glucose \~250 mg/dl) in the presence and absence of concomitant GLP-1 infusion. The investigators believe that the translational significance of their studies is immense, impacting upon both acute and chronic cardiovascular disease manifestations. The effect of glycemic control on cardiovascular outcomes, morbidity and mortality remains an area of active investigation, fueled by the recent conflicting results of several large clinical trials (ACCORD, United Kingdom Prospective Diabetes Study (UKPDS), ADVANCE, VADT). If the investigators find that hyperglycemia is associated with altered myocardial perfusion, the mechanistic implications in the prevention and management of acute and chronic cardiovascular diseases in DM will be groundbreaking. Furthermore, if GLP-1 augments myocardial perfusion (as it does in the peripheral vasculature), the therapeutic benefits for prevention of cardiovascular events in this predisposed population are clear.
Interventions
- DRUG Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2010-02 |
| Est. Completion | 2014-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01021865
The ClinicalTrials.gov registry entry for NCT01021865 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere is the first listed.
NCT01021865 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01021865 about?
NCT01021865 is a clinical study titled "Effects of Hyperglycemia on Myocardial Perfusion in Humans With and Without Type 2 Diabetes". The overall goal of this proposal is to determine the effects of acute hyperglycemia and its modulation by Glucagon-like Peptide-1 (GLP-1) on myocardial perfusion in type 2 diabetes (DM). This study plan utilizes myocardial contrast echocardiography (MCE) to explore a) the effects of acute hyperglyc...
What is the current status of trial NCT01021865?
This trial is currently completed. The enrollment target is 33 participants. The study started on 2010-02. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01021865?
The interventions under investigation include: Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere (DRUG).
Who is sponsoring clinical trial NCT01021865?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.